Novo Holdings, the parent company of Novo Nordisk, has received approval to proceed with its $16.5 billion acquisition of Catalent, a contract drug manufacturer. U.S. regulators have declined to challenge the deal, and the companies expect to close the transaction in the next few days. The European Commission has also approved the deal. The acquisition is aimed at addressing sporadic shortages of Novo Nordisk’s weight loss treatment, Wegovy, and concerns about competition in the pharmaceutical industry. The deal had faced scrutiny, but with regulatory conditions fulfilled, the acquisition is set to move forward.
Source link
Novo Holdings set to close $16.5 billion Catalent deal
